NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS EnglandcontractContracts FinderRef CF-2342700D0O000000rwimUAASME suitablecomplete
View buyer

Estimated value

£1.0bn

Awarded value

£1.0bn

Awarded 04 Apr 2024

Suppliers

1

Lots

1

1 awarded

Published

01 May 2024

Deadline 08 Dec 2023

Description

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024 Offer reference number: CM/PHR/22/5682 CM/PHR/22/5682/01 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 1. Period of framework: 1 May 2024 to 30 April 2028. CM/PHR/22/5682/02 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 2. Period of framework: 1 May 2024 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Scope

Reference
CF-2342700D0O000000rwimUAA
Total value
£1,009,500,000 excluding VAT
Commercial tool
Standalone contract
Contract dates
30 Apr 2024 to 29 Apr 2028
CPV classifications
33600000
Particular suitability
Small and medium-sized enterprises (SME)

Submission & procedure

Submission deadline
08 Dec 2023, 1:00 pm

Award details

Awarded supplier(s), contract period and value as published in the award notice.

Awarded value

£1.0bn

Award date

04 Apr 2024

Contract start

30 Apr 2024

Contract end

29 Apr 2028

Awarded to
DL
Day Lewis Medical Ltd,Drugsrus Ltd,Neon Healthcare Ltd,Bayer Plc,ennogen healthcare ltd,Fresenius Kabi Limited,Aventis Pharma ltd t/a Sanofi,Selective Supplies Ltd.,Rosemont Pharmaceuticals Limited,Martindale Pharma,Zentiva Pharma UK Ltd,Simple Pharma,Accord-UK Ltd,B. Braun Medical Limited,Janssen-Cilag Ltd,GlaxoSmithKline UK Limited,Roche Products Ltd,Pfizer Ltd,ORPHALAN UK LTD,Merck Sharpe & Dohme (UK) Limited,Flexipharm Austrading Limited,FLYNN PHARMA LTD,Aguettant Ltd,Mercury Pharmaceuticals Limited,Abbvie Ltd,Clinigen Healthcare Limited,Thornton and Ross Ltd,Sun Pharma UK Ltd,Valneva UK Ltd,Venture Healthcare Ltd,Glenmark Pharmaceuticals Europe Limited,Dexcel Pharma Ltd,Alan Pharmaceuticals,AOP Orphan Ltd,Brancaster Pharma Ltd,Stirling Anglian Pharmaceuticals Ltd,Ferndale Pharmaceuticals Ltd,Aspen Pharmacare UK Limited,Univar Solutions,Napp Pharmaceuticals Ltd,Morningside Pharmaeuticals,Kyowa Kirin Ltd,Biovantic Pharma Limited,Alliance Pharmaceuticals Limited,CST Pharma Limited,Waymade PLC,Biofrontera Pharma GmbH,Novartis Pharmaceuticals UK Ltd,Reckitt Benckiser,Teva UK Limited,Dr Falk Pharma UK Ltd,Novo Nordisk,Amarox Limited,Bausch + Lomb (Pharma),Fontus Health Ltd,A. Menarini Farmaceutica Internazionale SRL,Recordati Rare Diseases UK Ltd,Aspire Pharma Limited,Ferring Pharmaceuticals Ltd,Chiesi Limited,SERB SA,Sandoz Ltd,Amgen Ltd,Cipla (EU) Ltd,Colonis Pharma Ltd,Cenote Pharma Limited,AstraZeneca,Necessity Supplies Limited,Takeda UK Ltd,PARI,Tillotts Pharma UK Ltd,Lupin Healthcare (UK) Limited,Thea Pharmaceuticals Limited,Essential Pharma,Wockhardt UK Limited,Merck Serono Limited,Evolan Pharma,Organon Pharmaceuticals UK Ltd,Tillomed Laboratories ltd,Xiromed,Eli Lilly & Company Ltd,Pharmacosmos UK Ltd,Luye Pharma Ltd,Uni Health Distribution Ltd,Crescent Pharma Ltd,Focus Pharmaceuticals Ltd,Esteve Pharmaceuticals Ltd,Typharm Ltd,RPH Pharmaceuticals AB,Tetris Pharma Lts